Ken Fisher Alkermes Plc. Transaction History

Fisher Asset Management, LLC

$229 Billion
Q2 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Alkermes Plc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 242,638 shares of ALKS stock, worth $7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

242,638

Previous 213,437 13.68%

Holding current value

$7 Million

Previous $5.78 Million 1.21%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $677,755 - $795,435	29,201 Added 13.68%	242,638 $5.85 Million
Q1 2024 May 09, 2024	BUY	$26.4 - $32.56 $4.05 Million - $5 Million	153,495 Added 256.07%	213,437 $5.78 Million
Q4 2023 Feb 06, 2024	BUY	$23.37 - $28.68 $13,367 - $16,404	572 Added 0.96%	59,942 $1.66 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $1.86 Million - $2.19 Million	-68,544 Reduced 53.59%	59,370 $1.66 Million
Q2 2023 Dec 12, 2023	BUY	$28.34 - $33.63 $1.94 Million - $2.31 Million	68,544 Added 115.45%	127,914 $4 Million
Q2 2023 Aug 08, 2023	SELL	$28.34 - $33.63 $112,311 - $133,275	-3,963 Reduced 3.01%	127,914 $4 Million
Q1 2023 Dec 12, 2023	BUY	$25.31 - $29.02 $1.74 Million - $1.99 Million	68,556 Added 115.47%	127,926 $3.61 Million
Q1 2023 May 01, 2023	BUY	$25.31 - $29.02 $11,364 - $13,029	449 Added 0.34%	131,877 $3.72 Million
Q4 2022 Feb 03, 2023	BUY	$21.94 - $26.24 $612,718 - $732,804	27,927 Added 26.98%	131,428 $3.43 Million
Q3 2022 Nov 08, 2022	BUY	$22.0 - $31.87 $135,872 - $196,829	6,176 Added 6.35%	103,501 $2.31 Million
Q2 2022 Aug 09, 2022	BUY	$26.4 - $30.54 $334,752 - $387,247	12,680 Added 14.98%	97,325 $2.9 Million
Q1 2022 May 05, 2022	SELL	$23.07 - $27.99 $86,166 - $104,542	-3,735 Reduced 4.23%	84,645 $2.23 Million
Q4 2021 Feb 02, 2022	BUY	$21.47 - $32.08 $3,692 - $5,517	172 Added 0.19%	88,380 $2.06 Million
Q3 2021 Oct 26, 2021	SELL	$23.37 - $32.13 $13,905 - $19,117	-595 Reduced 0.67%	88,208 $2.72 Million
Q2 2021 Jul 27, 2021	BUY	$18.78 - $25.15 $95,834 - $128,340	5,103 Added 6.1%	88,803 $2.18 Million
Q1 2021 Apr 27, 2021	BUY	$18.21 - $23.2 $244,268 - $311,204	13,414 Added 19.08%	83,700 $1.56 Million
Q4 2020 Jan 29, 2021	BUY	$15.39 - $22.1 $692 - $994	45 Added 0.06%	70,286 $1.4 Million
Q3 2020 Nov 10, 2020	SELL	$16.16 - $20.66 $269,484 - $344,526	-16,676 Reduced 19.19%	70,241 $1.16 Million
Q1 2020 Apr 28, 2020	SELL	$13.06 - $21.24 $1,214 - $1,975	-93 Reduced 0.11%	86,917 $1.25 Million
Q4 2019 Feb 12, 2020	SELL	$17.29 - $21.74 $309,300 - $388,906	-17,889 Reduced 17.05%	87,010 $1.78 Million
Q3 2019 Oct 29, 2019	BUY	$19.51 - $24.28 $18,885 - $23,503	968 Added 0.93%	104,899 $2.05 Million
Q2 2019 Jul 30, 2019	BUY	$21.47 - $37.33 $322,050 - $559,950	15,000 Added 16.87%	103,931 $2.34 Million
Q1 2019 Apr 22, 2019	BUY	$28.4 - $36.49 $101,586 - $130,524	3,577 Added 4.19%	88,931 $3.25 Million
Q4 2018 Jan 25, 2019	BUY	$27.94 - $44.61 $640,748 - $1.02 Million	22,933 Added 36.74%	85,354 $2.52 Million
Q3 2018 Oct 24, 2018	SELL	$38.6 - $46.12 $771,073 - $921,293	-19,976 Reduced 24.24%	62,421 $2.65 Million
Q2 2018 Jul 09, 2018	SELL	$40.56 - $51.36 $374,368 - $474,052	-9,230 Reduced 10.07%	82,397 $3.39 Million
Q1 2018 May 11, 2018	SELL	$53.61 - $67.26 $6.68 Million - $8.39 Million	-124,693 Reduced 57.64%	91,627 $5.31 Million
Q1 2018 Apr 19, 2018	BUY	$53.61 - $67.26 $5.72 Million - $7.18 Million	106,733 Added 97.4%	216,320 $12.5 Million
Q4 2017 Jan 24, 2018	SELL	$47.69 - $55.39 $26,563 - $30,852	-557 Reduced 0.51%	109,587 $6 Million
Q3 2017 Oct 17, 2017	BUY	$49.16 - $54.45 $5.41 Million - $6 Million	110,144	110,144 $5.6 Million

Others Institutions Holding ALKS

# of Institutions

346

Shares Held

183M

Call Options Held

209K

Put Options Held

89.4K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.74B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account